Catalyst

Slingshot members are tracking this event:

Immune Design (IMDZ) to complete Phase 1 study of ID-LV305 in Patients with Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1 in August 2020

Source Link:
https://www.clinicaltrials.gov/ct2/show/NCT02122861?term=lv-305&rank=1

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
IMDZ
100%
SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details LV305 utilizes the Specific Antigen approach to activate the immune system against a tumor by generating cytotoxic T cells (CTLs) against the specific tumor-associated antigen. As a ZVex-based product, LV305 is highly specific for dendritic cells (DCs) and unable to integrate or replicate effectively. LV305 is engineered to selectively activate CTLs without inducing CTL exhaustion and with a desirable safety profile that is potentially an improvement over earlier vector approaches. In a preclinical efficacy model, LV305 reduced tumor burden of an NY-ESO-1 expressing tumor, and produced a material increase in antigen-specific CD8s, both in a dose-dependent matter.
http://immunedesign....
Additional Relevant Details Update on March 3 2018: Initially expected to complete in December 2017, it is now due for August 2020
https://www.clinical...
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Jul 28, 2020
Occurred Source:
https://www.tandfonline.com/doi/full/10.1080/2162402X.2020.1847846
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 1 Study, Lv305, Intradermal Lv305, Ny-eso-1 Cancers, Ny-eso, Melanoma, Sarcoma, Ovarian Cancer, Non-small Cell Lung Cancer
About Us
Media Center
Connect with Us
© 2024 Slingshot Insights. All rights reserved.